Cyclooxygenase 2 and the kidney

被引:104
作者
Breyer, MD
Harris, RC
机构
[1] Vanderbilt Univ, Sch Med, Div Nephrol, Nashville, TN 37232 USA
[2] Vet Adm Med Ctr, Div Nephrol, Nashville, TN 37203 USA
[3] Vet Adm Med Ctr, Dept Med, Nashville, TN 37203 USA
[4] Vet Adm Med Ctr, Dept Physiol & Mol Biophys, Nashville, TN 37203 USA
关键词
D O I
10.1097/00041552-200101000-00014
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Cyclooxygenase metabolizes arachidonic acid to a family of bioactive fatty acids designated prostaglandins. Two isoforms of cyclooxygenase exist, designated COX1 and COX2. These isoforms are expressed in distinct but important areas of the kidney. COX1 predominates in vascular smooth muscle and collecting ducts, whereas COX2 predominates in the macula densa and nearby cells in the cortical thick ascending limb. COX2 is also highly expressed in medullary interstitial cells. Whereas COX1 expression does not exhibit dynamic regulation, COX2 expression is subject to regulation by several environmental conditions, including salt intake, water intake, medullary tonicity, growth factors, cytokines, and adrenal steroids. Recently, COX2-selective non-steroidal antiinflammatory drugs have become widely available. Many of the renal effects of non-selective non-steroidal anti-inflammatory drugs (including sodium retention, decreased glomerular filtration rate, and effects on renin-angiotensin levels) appear to be mediated by the inhibition of COX2 rather than COX1. Therefore, in contrast to the gastro intestinal-sparing effects of COX2-selective non-steroidal anti-inflammatory drugs, when considering the kidney, the same caution must be applied when using COX2-selective inhibitors as has been used with traditional non-selective non-steroidal anti-inflammatory drugs. Curr Opin Nephrol Hypertens 10:89-98. (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:89 / 98
页数:10
相关论文
共 103 条
[81]  
SMITH WL, 1992, AM J PHYSIOL, V263, pF181
[82]   PROSTAGLANDIN AND THROMBOXANE FORMATION IN GLOMERULI FROM RATS WITH REDUCED RENAL MASS [J].
STAHL, RAK ;
KUDELKA, S ;
PARAVICINI, M ;
SCHOLLMEYER, P .
NEPHRON, 1986, 42 (03) :252-257
[83]   Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet - A randomized, controlled trial [J].
Swan, SK ;
Rudy, DW ;
Lasseter, KC ;
Ryan, CF ;
Buechel, KL ;
Lambrecht, LJ ;
Pinto, MB ;
Dilzer, SC ;
Obrda, O ;
Sundblad, KJ ;
Gumbs, CP ;
Ebel, DL ;
Quan, H ;
Larson, PJ ;
Schwartz, JI ;
Musliner, TA ;
Gertz, BJ ;
Brater, DC ;
Yao, SL .
ANNALS OF INTERNAL MEDICINE, 2000, 133 (01) :1-9
[84]   INDOMETHACIN-INDUCED PROSTAGLANDIN INHIBITION WITH HYPERKALEMIA - REVERSIBLE CAUSE OF HYPORENINEMIC HYPOALDOSTERONISM [J].
TAN, SY ;
SHAPIRO, R ;
FRANCO, R ;
STOCKARD, H ;
MULROW, PJ .
ANNALS OF INTERNAL MEDICINE, 1979, 90 (05) :783-785
[85]   GROWTH OF MADIN-DARBY CANINE KIDNEY EPITHELIAL-CELL (MDCK) LINE IN HORMONE-SUPPLEMENTED, SERUM-FREE MEDIUM [J].
TAUB, M ;
CHUMAN, L ;
SAIER, MH ;
SATO, G .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1979, 76 (07) :3338-3342
[86]  
Tomasoni S, 1998, J AM SOC NEPHROL, V9, P1202
[87]   Inhibition of macula densa-stimulated renin secretion by pharmacological blockade of cyclooxygenase-2 [J].
Traynor, TR ;
Smart, A ;
Briggs, JP ;
Schnermann, J .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 1999, 277 (05) :F706-F710
[88]  
Tufro A, 1999, J AM SOC NEPHROL, V10, P2125
[89]   PHARMACOLOGY - TOWARDS A BETTER ASPIRIN [J].
VANE, J .
NATURE, 1994, 367 (6460) :215-216
[90]   INHIBITION OF PROSTAGLANDIN SYNTHESIS AS A MECHANISM OF ACTION FOR ASPIRIN-LIKE DRUGS [J].
VANE, JR .
NATURE-NEW BIOLOGY, 1971, 231 (25) :232-&